Where does Univerza v Ljubjani rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Univerza v Ljubjani ranks #25,477 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Univerza v Ljubjani hold?

Univerza v Ljubjani holds 11 US utility patents granted between 2017 and 2025, spanning 20 technology areas.

What is Univerza v Ljubjani's Innovation Score?

Univerza v Ljubjani has an Innovation Score of 51.8 out of 100 (top 11% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Univerza v Ljubjani focus on?

Univerza v Ljubjani's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 4 patents, ranking #4,040 of 6,058 assignees active in that subclass. Grants appear in 20 CPC subclasses total.

Is Univerza v Ljubjani's patent grant rate increasing or decreasing?

Univerza v Ljubjani's recent grant velocity is +200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Univerza v Ljubjani's patents?

Univerza v Ljubjani's patents average 12.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Univerza v Ljubjani patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Univerza v Ljubjani

USPTO PatentsView assignee record - 11 granted patents across 20 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Univerza ranks #25,477 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 20 technology areas.

#25,477
of 49,997 US assignees by volume: Top 11%
by Innovation Score (51.8/100): 12.3
avg claims per patent: +200%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R25477 · Foreign Corporation #25,477 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #25,477/49,997
PHOTO-FINISH University of Denver
CPC-FOCUS A61P · 20 areas
INNOV-PAR 51.8/100
CLAIMS-RICH 12.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +200% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: University of Denver (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Univerza’s 51.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (17%) Velocity 20.0 pts (39%) Breadth 15.8 pts (31%) Claim depth 7.4 pts (14%)

Qualcomm Incorporated · highest

85
Univerza v Ljubjani · this assignee

52
3D Lighting… · lowest

7

What this shows Univerza's Innovation Score is 51.8/100 (top 11% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Univerza?

Each dot is one of Univerza’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Univerza’s own 12.3 claims/patent is at or below the 15.6 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Univerza vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Univerza's grants concentrate

Univerza v Ljubjani is a focused PatentsView assignee: 20 CPC subclasses with 36.4% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2022 (2 grants) versus a trough of 1 in 2017. By volume, Univerza sits between University of Denver and V.V.T. Med Ltd..

Univerza's three-year grant acceleration

Univerza v Ljubjani shows 5 grants in 2022–2024 against only 1 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

University of Den…

11
University of Flo…

11
University of Joh…

11
University of Kent

11
Uurmi Systems PVT

11
V-armed

11
V-grid Energy Sys…

11
V V T Med

11
Univerza v Ljubja… ◀

11

What this shows Univerza holds 11 patents at rank #25,462, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Univerza

By rank, the assignees closest to #25,462 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Univerza's primary technology class.

Univerza's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

52 Top 11% higher than 89% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Univerza v Ljubjani patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	9.1%
2018	1	9.1%
2021	1	9.1%
2022	2	18.2%
2023	1	9.1%
2024	2	18.2%
2025partial year	3	27.3%

Which technologies does Univerza v Ljubjani patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 4

C07K - Peptides 4

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07D - Heterocyclic Compounds 2

H02J - Circuit Arrangements OR Systems FOR Supplying OR Distributing Electric POWER; Systems FOR Storing Electric Energy 2

G01R - Measuring Electric VARIABLES; Measuring Magnetic Variables 2

G06F - Electric Digital Data Processing 2

C07C - Acyclic OR Carbocyclic Compounds 1

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 1

C08L - Compositions OF Macromolecular Compounds 1

D01F - Chemical Features IN THE Manufacture OF Artificial Filaments, Threads, Fibres, Bristles OR RIBBONS; Apparatus Specially Adapted FOR THE Manufacture OF Carbon Filaments 1

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

A01N - Preservation OF Bodies OF Humans OR Animals OR Plants OR Parts Thereof ; Biocides, e.g. AS Disinfectants, AS Pesticides OR AS Herbicides ; Pest Repellants OR ATTRACTANTS; Plant Growth Regulators 1

Y04S - Systems Integrating Technologies Related TO Power Network Operation, Communication OR Information Technologies FOR Improving THE Electrical Power Generation, Transmission, Distribution, Management OR Usage, i.e. Smart Grids 1

Top 15 of 20 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Univerza v Ljubjani's patent record in context - here's where to go next.

Univerza v Ljubjani's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 36.4% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #25,477 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Univerza v Ljubjani against University of Denver, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 51.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.